Spots Global Cancer Trial Database for An Open Study Assessing the Safety and Tolerability of U3-1784
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: An Open Study Assessing the Safety and Tolerability of U3-1784
Official Title: A Phase 1, Open-label, Two-part, Safety and Tolerability Study of U3-1784 in Patients With Advanced Solid Tumours
Study ID: NCT02690350
Interventions
Study Description
Brief Summary: The main objectives of the trial are: * To evaluate the safety and tolerability of U3-1784 in patients with advanced solid tumours * To determine the maximum tolerated dose (MTD) and or establish the safety and tolerability of the maximum administered dose (MAD) of U3-1784
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, Glasgow, Lanarkshire, United Kingdom
The Royal Marsden Hospital, Sutton, Surrey, United Kingdom
Guy's Hospital, London, , United Kingdom
The Christie NHS Foundation Trust, Manchester, , United Kingdom
Contact Details
Name: Alberto Martinez, PhD
Affiliation: Daiichi Sankyo UK Ltd.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
